A growing body of evidence has demonstrated that the commensal microbiome is deeply involved in the host immune response, accounting for significantly divergent clinical outcomes among cancer patients receiving immunotherapy. Therefore, precise screening and evaluating of functional bacterial strains as novel targets for cancer immunotherapy have attracted great enthusiasm from both academia and industry, which calls for the construction and application of advanced animal models to support translational research in this field.
Recent Advances:
Significant progress has been made to elucidate the intervention effect of commensal microbiome on immunotherapy based on animal experiments. Especially, correlation between gut microbiota and host response to immunotherapy has been continuously discovered in a variety of cancer types, laying the foundation for causality establishment and mechanism research.
Critical Issues:
In oncology research, it is particularly not uncommon to see that a promising preclinical result fails to translate into clinical success. The use of conventional murine models in immunotherapy-associated microbiome research is very likely to bring discredit on the preclinical findings. We emphasize the value of germ-free (GF) mice and humanized mice as advanced models in this field.
Future Directions:
Integrating rederivation and humanization to generate humanized GF mice as preclinical models would make it possible to clarify the role of specific bacterial strains in immunotherapy as well as obtain preclinical findings that are more predictive for humans, leading to novel microbiome-based strategies for cancer immunotherapy. Antioxid. Redox Signal. 37, 1291–1302.
Get full access to this article
View all access options for this article.
References
1.
AbidMB, ShahNN, MaatmanTC, et al.Gut microbiome and CAR-T therapy. Exp Hematol Oncol, 2019; 8:31; doi: 10.1186/s40164-019-0155-8.
2.
Abu-SbeihH, AliFS, LuoW, et al.Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer, 2018; 6(1):95; doi: 10.1186/s40425-018-0411-1.
3.
Al-AsmakhM, ZadjaliF. Use of germ-free animal models in microbiota-related research. J Microbiol Biotechnol, 2015; 25(10):1583–1588; doi: 10.4014/jmb.1501.01039.
AudigeA, RochatMA, LiD, et al.Long-term leukocyte reconstitution in NSG mice transplanted with human cord blood hematopoietic stem and progenitor cells. BMC Immunol, 2017; 18(1):28; doi: 10.1186/s12865-017-0209-9.
6.
BarhamWJ, HarringtonSM, LiuX, et al. Humanized PD-1/PD-L1 (HuPD) mice facilitate the direct functional comparison of immune checkpoint inhibitors in vivo. J Immunol, 2019;202(1 Supplement):195.1.
7.
BaruchEN, YoungsterI, Ben-BetzalelG, et al.Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science, 2021; 371(6529):602–609; doi: 10.1126/science.abb5920.
8.
BergM, StenuitB, HoJ, et al.Assembly of the Caenorhabditis elegans gut microbiota from diverse soil microbial environments. ISME J, 2016; 10(8):1998–2009; doi: 10.1038/ismej.2015.253.
9.
BilenM, DufourJC, LagierJC, et al.The contribution of culturomics to the repertoire of isolated human bacterial and archaeal species. Microbiome, 2018; 6(1):94; doi: 10.1186/s40168-018-0485-5.
10.
BorcomanE, KanjanapanY, ChampiatS, et al.Novel patterns of response under immunotherapy. Ann Oncol, 2019; 30(3):385–396; doi: 10.1093/annonc/mdz003.
11.
BosmaGC, CusterRP, BosmaMJ. A severe combined immunodeficiency mutation in the mouse. Nature, 1983; 301(5900):527–530; doi: 10.1038/301527a0.
12.
BrehmMA, AryeeK-E, BruzenksiL, et al. Transgenic expression of human IL15 in NOD-scid IL2rgnull (NSG) mice enhances the development and survival of functional human NK cells. J Immunol, 2018;200(1 Supplement):103.20.
13.
BrownME, ZhouY, McintoshBE, et al.A humanized mouse model generated using surplus neonatal tissue. Stem Cell Reports, 2018; 10(4):1175–1183; doi: 10.1016/j.stemcr.2018.02.011.
14.
ByrneAT, AlferezDG, AmantF, et al.Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer, 2017; 17(4):254–268; doi: 10.1038/nrc.2016.140.
15.
ChangAE, GolobJL, SchmidtTM, et al.Targeting the gut microbiome to mitigate immunotherapy-induced colitis in cancer. Trends Cancer, 2021; 7(7):583–593; doi: 10.1016/j.trecan.2021.02.005.
16.
ChenX, YangS, LiS, et al.Secretion of bispecific protein of anti-PD-1 fused with TGF-beta trap enhances antitumor efficacy of CAR-T cell therapy. Mol Ther Oncolytics, 2021; 21:144–157; doi: 10.1016/j.omto.2021.03.014.
17.
ChoiJG, KimYS, KimJH, et al.Anticancer effect of Salvia plebeia and its active compound by improving T-cell activity via blockade of PD-1/PD-L1 interaction in humanized PD-1 mouse model. Front Immunol, 2020; 11:598556; doi: 10.3389/fimmu.2020.598556.
18.
ClavelT, Gomes-NetoJC, LagkouvardosI, et al.Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes. Immunol Rev, 2017; 279(1):8–22; doi: 10.1111/imr.12578.
19.
DavarD, DzutsevAK, MccullochJA, et al.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science, 2021; 371(6529):595–602; doi: 10.1126/science.abf3363.
20.
DholakiaJ, ScaliseC, ArendRC. Assessing preclinical research models for immunotherapy for gynecologic malignancies. Cancers (Basel), 2021; 13(7):1694; doi: 10.3390/cancers13071694.
21.
DoboszP, DzieciatkowskiT. The intriguing history of cancer immunotherapy. Front Immunol, 2019; 10:2965; doi: 10.3389/fimmu.2019.02965.
22.
DouganM, WangY, Rubio-TapiaA, et al.AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review. Gastroenterology, 2021; 160(4):1384–1393; doi: 10.1053/j.gastro.2020.08.063.
23.
DubinK, CallahanMK, RenB, et al.Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun, 2016; 7:10391; doi: 10.1038/ncomms10391.
24.
ElkriefA, RoutyB. First clinical proof-of-concept that FMT can overcome resistance to ICIs. Nat Rev Clin Oncol, 2021; 18(6):325–326; doi: 10.1038/s41571-021-00502-3.
25.
EvrardYA, SrivastavaA, RandjelovicJ, et al.Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis. Cancer Res, 2020; 80(11):2286–2297; doi: 10.1158/0008-5472.CAN-19-3101.
26.
FengM, JiangW, KimBYS, et al.Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer, 2019; 19(10):568–586; doi: 10.1038/s41568-019-0183-z.
27.
FillonM. Fecal microbiota transplants may aid melanoma immunotherapy resistance. CA Cancer J Clin, 2021; 71(4):285–286; doi: 10.3322/caac.21676.
28.
FlanaganSP. ‘Nude’, a new hairless gene with pleiotropic effects in the mouse. Genet Res, 1966; 8(3):295–309.
29.
GhoshS, SharmaG, TraversJ, et al.TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo. Mol Cancer Ther, 2019; 18(3):632–641; doi: 10.1158/1535-7163.MCT-18-0836.
30.
GopalakrishnanV, SpencerCN, NeziL, et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2018; 359(6371):97–103; doi: 10.1126/science.aan4236.
31.
GroisbergR, MaitraA, SubbiahV. Of mice and men: Lost in translation. Ann Oncol, 2019; 30(4):499–500; doi: 10.1093/annonc/mdz041.
32.
HanazawaA, ItoR, KatanoI, et al.Generation of human immunosuppressive myeloid cell populations in human interleukin-6 transgenic NOG mice. Front Immunol, 2018; 9:152; doi: 10.3389/fimmu.2018.00152.
33.
HaslamA, PrasadV. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open, 2019; 2(5):e192535; doi: 10.1001/jamanetworkopen.2019.2535.
34.
HeX, XuC. Immune checkpoint signaling and cancer immunotherapy. Cell Res, 2020; 30(8):660–669; doi: 10.1038/s41422-020-0343-4.
35.
HeY, FuL, LiY, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab, 2021;33(5):988.e7–1000.e7; doi: 10.1016/j.cmet.2021.03.002.
36.
HuangJ, LiuD, WangY, et al.Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut, 2022; 71:734–745; doi: 10.1136/gutjnl-2020-321031.
37.
InnaoV, AllegraAG, MusolinoC, et al.New frontiers about the role of human microbiota in immunotherapy: The immune checkpoint inhibitors and CAR T-cell therapy era. Int J Mol Sci, 2020; 21(23):8902; doi: 10.3390/ijms21238902.
38.
InzunzaJ, MidtvedtT, FartooM, et al.Germfree status of mice obtained by embryo transfer in an isolator environment. Lab Anim, 2005; 39(4):421–427; doi: 10.1258/002367705774286439.
39.
ItoM, HiramatsuH, KobayashiK, et al.NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood, 2002; 100(9):3175–3182; doi: 10.1182/blood-2001-12-0207.
40.
JangalweS, ShultzLD, MathewA, et al.Improved B cell development in humanized NOD-scid IL2Rgamma(null) mice transgenically expressing human stem cell factor, granulocyte-macrophage colony-stimulating factor and interleukin-3. Immun Inflamm Dis, 2016; 4(4):427–440; doi: 10.1002/iid3.124.
41.
JiaPP, JunaidM, WenPP, et al.Role of germ-free animal models in understanding interactions of gut microbiota to host and environmental health: A special reference to zebrafish. Environ Pollut, 2021; 279:116925; doi: 10.1016/j.envpol.2021.116925.
42.
KalscheuerH, DanzlN, OnoeT, et al.A model for personalized in vivo analysis of human immune responsiveness. Sci Transl Med, 2012; 4(125):125ra30; doi: 10.1126/scitranslmed.3003481.
43.
KamareddineL, NajjarH, SohailMU, et al.The microbiota and gut-related disorders: insights from animal models. Cells, 2020; 9(11):2401; doi: 10.3390/cells9112401.
44.
KatanoI, ItoR, KawaiK, et al.Improved detection of in vivo human NK cell-mediated antibody-dependent cellular cytotoxicity using a novel NOG-FcgammaR-deficient human IL-15 transgenic mouse. Front Immunol, 2020; 11:532684; doi: 10.3389/fimmu.2020.532684.
45.
KatanoI, NishimeC, ItoR, et al.Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Sci Rep, 2017; 7(1):17230; doi: 10.1038/s41598-017-17442-7.
46.
KimCG, KimKH, PyoKH, et al.Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol, 2019; 30(7):1104–1113; doi: 10.1093/annonc/mdz123.
47.
KingMA, CovassinL, BrehmMA, et al.Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol, 2009; 157(1):104–118; doi: 10.1111/j.1365-2249.2009.03933.x.
48.
KondoM, SchererDC, KingAG, et al.Lymphocyte development from hematopoietic stem cells. Curr Opin Genet Dev, 2001; 11(5):520–526; doi: 10.1016/s0959-437x(00)00227-6.
49.
KostrzewaM, NagyE, SchrottnerP, et al.B. How MALDI-TOF mass spectrometry can aid the diagnosis of hard-to-identify pathogenic bacteria—The rare and the unknown. Expert Rev Mol Diagn, 2019; 19(8):667–682; doi: 10.1080/14737159.2019.1643238.
50.
KuczmaMP, DingZ-C, LiT, et al.The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. Oncotarget, 2017; 8(67):111931–111942.
51.
LagierJC, DubourgG, MillionM, et al.Culturing the human microbiota and culturomics. Nat Rev Microbiol, 2018; 16:540–550; doi: 10.1038/s41579-018-0041-0.
52.
LagierJC, KhelaifiaS, AlouMT, et al.Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol, 2016; 1:16203; doi: 10.1038/nmicrobiol.2016.203.
53.
LamKC, ArayaRE, HuangA, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell, 2021;184(21):5338.e21–5356.e21; doi: 10.1016/j.cell.2021.09.019.
54.
LavenderKJ, MesserRJ, RaceB, et al.Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2(−/−)gammac(−/−)CD47(−/−) background. J Immunol Methods, 2014; 407:127–134; doi: 10.1016/j.jim.2014.04.008.
55.
LeclercqS, MianFM, StaniszAM, et al.Low-dose penicillin in early life induces long-term changes in murine gut microbiota, brain cytokines and behavior. Nat Commun, 2017; 8:15062; doi: 10.1038/ncomms15062.
56.
LedfordH. US cancer institute to overhaul tumour cell lines. Nature, 2016; 530(7591):391; doi: 10.1038/nature.2016.19364.
57.
LeeHY, LeeSH, LeeJH, et al.The role of commensal microbes in the lifespan of Drosophila melanogaster. Aging (Albany NY), 2019; 11(13):4611–4640; doi: 10.18632/aging.102073.
58.
LegrandN, HuntingtonND, NagasawaM, et al.Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo. Proc Natl Acad Sci U S A, 2011; 108(32):13224–13229; doi: 10.1073/pnas.1101398108.
59.
LiJ, WeiH. Establishment of an efficient germ-free animal system to support functional microbiome research. Sci China Life Sci, 2019; 62(10):1400–1403; doi: 10.1007/s11427-019-9832-9.
60.
LiaoX, SongL, ZengB, et al.Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis. EBioMedicine, 2019; 44:665–674; doi: 10.1016/j.ebiom.2019.03.057.
61.
LinS, HuangG, ChengL, et al.Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs, 2018; 10(8):1301–1311; doi: 10.1080/19420862.2018.1518948.
62.
LuuM, RiesterZ, BaldrichA, et al.Microbial short-chain fatty acids modulate CD8(+) T cell responses and improve adoptive immunotherapy for cancer. Nat Commun, 2021; 12(1):4077; doi: 10.1038/s41467-021-24331-1.
63.
MartellacciL, QuarantaG, PatiniR, et al.A literature review of metagenomics and culturomics of the peri-implant microbiome: Current evidence and future perspectives. Materials (Basel), 2019; 12(18):3010; doi: 10.3390/ma12183010.
64.
MaserIP, HovesS, BayerC, et al.The tumor milieu promotes functional human tumor-resident plasmacytoid dendritic cells in humanized mouse models. Front Immunol, 2020; 11:2082; doi: 10.3389/fimmu.2020.02082.
65.
MatsonV, FesslerJ, BaoR, et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science, 2018; 359(6371):104–108; doi: 10.1126/science.aao3290.
66.
MaudeSL, LaetschTW, BuechnerJ, et al.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med, 2018; 378(5):439–448; doi: 10.1056/NEJMoa1709866.
67.
MayesPA, HanceKW, HoosA. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov, 2018; 17(7):509–527; doi: 10.1038/nrd.2018.75.
68.
McCuneJM, NamikawaR, KaneshimaH, et al.The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science, 1988; 241(4873):1632–1639; doi: 10.1126/science.241.4873.1632.
69.
McDermottAJ, HuffnagleGB. The microbiome and regulation of mucosal immunity. Immunology, 2014; 142(1):24–31; doi: 10.1111/imm.12231.
70.
McGowanE, LinQ, MaG, et al.PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomed Pharmacother, 2020; 121:109625; doi: 10.1016/j.biopha.2019.109625.
71.
MelanconE, Gomez de la Torre CannyS, SichelS, et al.Best practices for germ-free derivation and gnotobiotic zebrafish husbandry. Methods Cell Biol, 2017; 138:61–100; doi: 10.1016/bs.mcb.2016.11.005.
72.
MellmanI, CoukosG, DranoffG. Cancer immunotherapy comes of age. Nature, 2011; 480(7378):480–489; doi: 10.1038/nature10673.
73.
MerazIM, MajidiM, MengF, et al.An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses. Cancer Immunol Res, 2019; 7(8):1267–1279; doi: 10.1158/2326-6066.CIR-18-0874.
74.
MichotJM, BigenwaldC, ChampiatS, et al.Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer, 2016; 54:139–148; doi: 10.1016/j.ejca.2015.11.016.
75.
NeelapuSS, LockeFL, BartlettNL, et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med, 2017; 377(26):2531–2544; doi: 10.1056/NEJMoa1707447.
76.
NejmanD, LivyatanI, FuksG, et al.The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science, 2020; 368(6494):973–980; doi: 10.1126/science.aay9189.
77.
OisethSJ, AzizMS. Cancer immunotherapy: A brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat, 2017; 3(10):250–261; doi: 10.20517/2394-4722.2017.41.
78.
PetkauK, FergusonM, GuntermannS, et al.Constitutive immune activity promotes tumorigenesis in drosophila intestinal progenitor cells. Cell Rep, 2017; 20(8):1784–1793; doi: 10.1016/j.celrep.2017.07.078.
79.
PostowMA, SidlowR, HellmannMD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med, 2018; 378(2):158–168; doi: 10.1056/NEJMra1703481.
80.
RibasA, HamidO, DaudA, et al.Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA, 2016; 315(15):1600–1609; doi: 10.1001/jama.2016.4059.
81.
RisbridgerGP, LawrenceMG, TaylorRA. PDX: Moving beyond drug screening to versatile models for research discovery. J Endocr Soc, 2020; 4(11):bvaa132; doi: 10.1210/jendso/bvaa132.
82.
RoundJL, PalmNW. Causal effects of the microbiota on immune-mediated diseases. Sci Immunol, 2018; 3(20):eaao1603; doi: 10.1126/sciimmunol.aao1603.
83.
RoutyB, Le ChatelierE, DerosaL, et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 2018; 359(6371):91–97; doi: 10.1126/science.aan3706.
84.
RovielloG, IannoneLF, BersanelliM, et al.The gut microbiome and efficacy of cancer immunotherapy. Pharmacol Ther, 2022; 231:107973; doi: 10.1016/j.pharmthera.2021.107973.
85.
SadelainM. CD19 CAR T cells. Cell, 2017; 171(7):1471; doi: 10.1016/j.cell.2017.12.002.
86.
SanmamedMF, ChenL. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell, 2018; 175(2):313–326; doi: 10.1016/j.cell.2018.09.035.
87.
Sepich-PooreGD, ZitvogelL, StraussmanR, HastyJ, WargoJA, KnightR. The microbiome and human cancer. Science. 2021;371(6536); doi: 10.1126/science.abc4552.
88.
SeyhanAA. Lost in translation: The valley of death across preclinical and clinical divide—Identification of problems and overcoming obstacles. Transl Med Commun, 2019; 4(1):18; doi: 10.1186/s41231-019-0050-7.
89.
ShiY, ZhengW, YangK, et al.Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med, 2020; 217(5):e20192282; doi: 10.1084/jem.20192282.
ShultzLD, KeckJ, BurzenskiL, et al.Humanized mouse models of immunological diseases and precision medicine. Mamm Genome, 2019; 30(5–6):123–142; doi: 10.1007/s00335-019-09796-2.
92.
ShultzLD, LyonsBL, BurzenskiLM, et al.Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol, 2005; 174(10):6477–6489; doi: 10.4049/jimmunol.174.10.6477.
93.
ShultzLD, SchweitzerPA, ChristiansonSW, et al.Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol, 1995; 154(1):180–191.
94.
SmithM, LittmannER, SlingerlandJB, et al.Intestinal microbiota composition prior to CAR T cell infusion correlates with efficacy and toxicity. Blood, 2018; 132(Supplement 1):3492; doi: 10.1182/blood-2018-99-118628.
95.
StripeckeR, MunzC, SchuringaJJ, et al.Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol Med, 2020; 12(7):e8662; doi: 10.15252/emmm.201708662.
96.
SuarezER, Chang DeK, SunJ, et al.Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget, 2016; 7(23):34341–34355; doi: 10.18632/oncotarget.9114.
97.
SunN, HuH, WangF, et al.Antibiotic-induced microbiome depletion in adult mice disrupts blood-brain barrier and facilitates brain infiltration of monocytes after bone-marrow transplantation. Brain Behav Immun, 2021; 92:102–114; doi: 10.1016/j.bbi.2020.11.032.
98.
SzteinJM, KastenmayerRJ, PerdueKA. Pathogen-Free Mouse Rederivation by IVF, Natural Mating and Hysterectomy. In: Advanced Protocols for Animal Transgenesis, edited by Pease S and Saunders TL. Springer-Verlag Berlin Heidelberg: Saunders Publisher, 2011, pp. 615–642.
99.
TanoueT, MoritaS, PlichtaDR, et al.A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature, 2019; 565(7741):600–605; doi: 10.1038/s41586-019-0878-z.
100.
Tidjani AlouM, NaudS, KhelaifiaS, et al.State of the art in the culture of the human microbiota: New interests and strategies. Clin Microbiol Rev, 2020; 34(1):e00129-19; doi: 10.1128/CMR.00129-19.
101.
TsayJJ, WuBG, SulaimanI, et al.Lower airway dysbiosis affects lung cancer progression. Cancer Discov, 2021; 11(2):293–307; doi: 10.1158/2159-8290.CD-20-0263.
102.
VaddepallyRK, KharelP, PandeyR, et al.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel), 2020; 12(3):738; doi: 10.3390/cancers12030738.
103.
VetizouM, PittJM, DaillereR, et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015; 350(6264):1079–1084; doi: 10.1126/science.aad1329.
104.
WaldmanAD, FritzJM, LenardoMJ. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol, 2020; 20(11):651–668; doi: 10.1038/s41577-020-0306-5.
105.
WalterJ, ArmetAM, FinlayBB, et al.Establishing or exaggerating causality for the gut microbiome: Lessons from human microbiota-associated rodents. Cell, 2020; 180(2):221–232; doi: 10.1016/j.cell.2019.12.025.
106.
WangT, ZhengN, LuoQ, et al.Probiotics Lactobacillus reuteri abrogates immune checkpoint blockade-associated colitis by inhibiting group 3 innate lymphoid cells. Front Immunol, 2019; 10:1235; doi: 10.3389/fimmu.2019.01235.
107.
WangY, WiesnoskiDH, HelminkBA, et al.Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med, 2018; 24(12):1804–1808; doi: 10.1038/s41591-018-0238-9.
108.
WeaverJL, ZadroznyLM, GabrielsonK, et al.BLT-immune humanized mice as a model for nivolumab-induced immune-mediated adverse events: Comparison of the NOG and NOG-EXL strains. Toxicol Sci, 2019; 169(1):194–208; doi: 10.1093/toxsci/kfz045.
109.
WeiSC, DuffyCR, AllisonJP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov, 2018; 8(9):1069–1086; doi: 10.1158/2159-8290.CD-18-0367.
110.
WienholdSM, MacriM, NouaillesG, et al.Ventilator-induced lung injury is aggravated by antibiotic mediated microbiota depletion in mice. Crit Care, 2018; 22(1):282; doi: 10.1186/s13054-018-2213-8.
111.
WoelkCH, SnyderA. Modulating gut microbiota to treat cancer. Science, 2021; 371(6529):573–574; doi: 10.1126/science.abg2904.
112.
WuC, ShangH, JiangX, et al.2021a. Application of germ-free NOD-scid IL2rg(null) mice as a humanized model for tumor microbiome precision medicine. Sci China Life Sci, 2021; 64(4):644–647; doi: 10.1007/s11427-020-1876-1.
113.
WuG, ZhaoN, ZhangC, et al.2021b. Guild-based analysis for understanding gut microbiome in human health and diseases. Genome Med, 2021; 13(1):22; doi: 10.1186/s13073-021-00840-y.
114.
YamauchiT, TakenakaK, UrataS, et al.Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood, 2013; 121(8):1316–1325; doi: 10.1182/blood-2012-06-440354.
115.
YanH, SempleKM, GonzalezCM, et al.Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome. Transl Res, 2019; 210:43–56; doi: 10.1016/j.trsl.2019.04.007.
116.
YaoL-C, ChengM, ShultzLD, et al.Abstract B72: Humanized NSG-Tg(Hu-IL15) mice support preclinical immune-oncology efficacy for testing of NK cell-based immunotherapy. Cancer Immunol Res, 2020; 8(3 Supplement):B72; doi: 10.1158/2326-6074.Tumimm19-b72.
117.
YoshimiA, BalasisME, VedderA, et al.Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood, 2017; 130(4):397–407; doi: 10.1182/blood-2017-01-763219.
118.
YuH, BorsottiC, SchickelJN, et al.A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood, 2017; 129(8):959–969; doi: 10.1182/blood-2016-04-709584.
119.
ZhaoR, CokerOO, WuJ, et al. Aspirin reduces colorectal tumor development in mice and gut microbes reduce its bioavailability and chemopreventive effects. Gastroenterology, 2020;159(3):969.e4–983.e4; doi: 10.1053/j.gastro.2020.05.004.
120.
ZhaoY, ShuenTWH, TohTB, et al.Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut, 2018; 67(10):1845–1854; doi: 10.1136/gutjnl-2017-315201.
121.
ZhengP, ZengB, LiuM, et al.The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv, 2019; 5(2):eaau8317; doi: 10.1126/sciadv.aau8317.
122.
ZhouCB, ZhouYL, FangJY. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer, 2021; 7(7):647–660; doi: 10.1016/j.trecan.2021.01.010.
